✦ LIBER ✦

Talsaclidine (WAL 2014 FU), a muscarinic M1 receptor agonist for the treatment of Alzheimer's disease

✍ Scribed by Marion Wienrich; Angelo Ceci; Helmut A. Ensinger; Wolfram Gaida; Klaus D. Mendla; Takeshi Osugi; Andreas Raschig; Thomas Weiser

Publisher: John Wiley and Sons
Year: 2002
Tongue: English
Weight: 212 KB
Volume: 56
Category: Article
ISSN: 0272-4391
DOI: 10.1002/ddr.10085

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

WAL 2014 FU (talsaclidine): A preferenti

WAL 2014 FU (talsaclidine): A preferentially neuron activating muscarinic agonist for the treatment of Alzheimer's disease

✍ Helmut A. Ensinger; Wolf-Dieter Bechtel; Franz W. Birke; Klaus D. Mendla; Joachi 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 150 KB 👁 2 views

The functional selectivity of WAL 2014 FU with regard to stimulation of the neuronal muscarinic M 1 receptor subtype in vitro and in vivo is shown in different receptor preparations, isolated organ models, whole animal testing, and finally humans. From receptor binding experiments in membrane prepar

Xanomeline: A selective muscarinic agoni

Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease

✍ Frank P. Bymaster; Celia A. Whitesitt; Harlan E. Shannon; Neil DeLapp; John S. W 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB 👁 3 views

Xanomeline is a novel muscarinic receptor agonist relatively devoid of parasympathomimetic side effects. Xanomeline had high affinity for muscarinic receptors and much lower affinity for a variety of other neuronal receptors in radioligand binding assays. Functional studies in cell lines transfected

Development of CDD-0102 as a selective M

Development of CDD-0102 as a selective M1 agonist for the treatment of Alzheimer's disease

✍ William S. Messer Jr.; Kenneth A. Bachmann; Colleen Dockery; Afif A. El-Assadi; 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB 👁 1 views

## Abstract Selective muscarinic agonists might be useful in the treatment of Alzheimer's disease. To help characterize the activity and functional selectivity of two M~1~ muscarinic agonists, secretion of amyloid precursor protein, brain penetration, side effect profiles, cognition‐enhancing prope

Orally active and selective benzylidene

Orally active and selective benzylidene ketal M2 muscarinic receptor antagonists for the treatment of Alzheimer's disease

✍ Craig D. Boyle; Jean E. Lachowicz 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB

Loss of high-affinity agonist binding to

Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: Implications for the failure of cholinergic replacement therapies

✍ Donna D. Flynn; David A. Weinstein; Dr Deborah C. Mash 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 706 KB

The selective muscarinic M1 agonist AF10

The selective muscarinic M1 agonist AF102B decreases levels of total Aβ in cerebrospinal fluid of patients with Alzheimer's disease

✍ Roger M. Nitsch; Meihua Deng; Marsha Tennis; David Schoenfeld; John H. Growdon 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 1 views